ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

FDA Approves Lapatinib For Advanced Breast Cancer

March 30, 2007

Report Urges Better Working Conditions For Postdocs.

October 6, 2000

Nimer to Lead Miami Sylvester Cancer Center

March 9, 2012

GA Draft Report Lukewarm On Cancer Survival Improvement; NCI Says It Is “Opinion, Not Fact”

April 3, 1987

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005